Navigation Links
Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes
Date:11/4/2010

SAN DIEGO, Nov. 4, 2010 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that, following the completion of a Phase 1 clinical trial program for APD597 (JNJ-38431055) under its collaboration with Arena, Ortho-McNeil-Janssen Pharmaceuticals, Inc., has decided not to advance APD597 and has notified Arena that it is terminating the collaboration, effective December 28, 2010. APD597 is a GPR119 agonist intended for the treatment of type 2 diabetes, which, along with other compounds and intellectual property, will revert to Arena upon termination of the collaboration. Arena owns a patent portfolio covering a broad array of internally discovered, oral GPR119 agonists, including next generation compounds that were not part of the collaboration.

The Phase 1 program evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of APD597, and included single and multi-ascending studies in healthy volunteers and in subjects with type 2 diabetes. APD597 was well tolerated and showed dose-proportional pharmacokinetics with a half-life of six to seven hours in solution and approximately 13 hours in suspension in healthy volunteers. The Phase 1 program also provided evidence for incretin stimulation (GLP-1, GIP and PYY) and reductions in post-meal glucose increases with APD597 treatment in both overweight and obese non-diabetic volunteers and in subjects with type 2 diabetes. In general, reductions in post-meal glucose increases were greater with APD597 in combination with sitagliptin, a DPP-4 inhibitor, compared to sitagliptin alone.

"Results of the Phase 1 program suggest that APD597 may have utility both alone and in combination with a DPP-4 inhibitor for the treatment of type 2 diabetes," said Jack Lief, Arena's President and Chief Executive Officer. "With our existing GPR119 patent portfolio, internally discovered next generation compounds a
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Endologix Announces Publication of Clinical Trial Results Supporting Anatomical Fixation with a Suprarenal Aortic Extension
2. Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010
3. Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting
4. Arena Pharmaceuticals to Host Conference Call and Webcast Following Lorcaserin FDA Advisory Committee Meeting
5. Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
6. Published Data Demonstrate Arena Pharmaceuticals Lorcaserin Has Low Abuse Potential
7. Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009
9. Arena Pharmaceuticals Lorcaserin to be Featured in Multiple Presentations at Obesity 2009
10. Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
11. Arena Pharmaceuticals to Host Conference Call and Webcast on Friday, September 18, 2009, to Discuss Results from the BLOSSOM Phase 3 Trial of Lorcaserin for Weight Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , August 29, 2014 ... Oil Market by Extraction type (SFE, Cold Pressed, ... Personal Care, Pharmaceutical, Food Supplements, Fragrance, & Others) - ... MarketsandMarkets, defines and segments the Amaranth Seed Oil ... market size in terms of value. The Amaranth ...
(Date:8/29/2014)... 29, 2014   Vittamed Corporation , a neurodiagnostics medical ... today that T. (Teo) Forcht Dagi , MD, DmedSc, ... of Directors. " Teo Forcht Dagi ... medical innovation and venture capital," said Remis Bistras , ... add his clinical, strategic, and entrepreneurial expertise to our Board." ...
(Date:8/29/2014)... PITTSBURGH , Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage ... at the Australian and New Zealand Forensic Science ... Forensic Sciences in Adelaide, Australia ... discussion concerning the advancements that hyperspectral imaging can ... Jeffrey Beckstead , Director of Product Development ...
Breaking Medicine Technology:Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
... (NASDAQ: IPHS ), the leading North American ... pharmaceutical, oral care and industrial end markets, today announced ... completed the acquisition of Kelatron Corporation. Kelatron ... of bioactive mineral nutrients. For over 30 years, the ...
... Filtrona Porous Technologies, a developer and manufacturer of custom ... will introduce a new range of hydrophilic, polyurethane foams ... COMPAMED trade fair in Dusseldorf, Germany from 16 to ... New innovations to be featured at ...
Cached Medicine Technology:Innophos Holdings, Inc. Announces Acquisition of Kelatron Corporation 2Filtrona Porous Technologies to Introduce New Hydrophilic Foam Products for Advanced Wound Care at the MEDICA / COMPAMED Trade Fair 2
(Date:9/1/2014)... 01, 2014 An operating theatre or ... for performing surgical operations. An operating room comprises a ... booms, operating room lights, imaging displays as well as ... by Transparency Market Research, a U.S.-based market research firm, ... USD 4.5 billion by 2019. , According to ...
(Date:9/1/2014)... "Women struggle with weight gain typically associated to ... early as 15, if not earlier. Women therefore ... downs of hormone related weight gain. The battle ... to rage against the hidden and ever-present hormones which ... begin to face menopause and related changes, these hormonal ...
(Date:9/1/2014)... By Dennis Thompson ... -- An experimental Ebola drug previously given to two American ... the deadly virus in laboratory tests, researchers report. The ... it, even if they didn,t get the medication until five ... cases of Ebola who were days or even hours away ...
(Date:9/1/2014)... atrial fibrillation (AF) doubles the risk of stroke compared ... 6 000 patients presented at ESC Congress today by ... a simple clinical assessment of the type of AF ... Ischaemic stroke is the second cause of death in ... many more disabled patients each year. Annual direct health ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 The National ... to announce that Dawn Bazarko, DNP, MPH, RN, and ... of the American Academy of Nursing. They will be ... RN-BC, CCM, FACHE, whose induction we reported last May. ... 18, 2014, during the 2014 American Academy of Nursing ...
Breaking Medicine News(10 mins):Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 3Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 2Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 3Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3Health News:Permanent AF doubles risk of stroke compared to paroxysmal AF 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4
... go indoors, , , SATURDAY, July 12 (HealthDay News) -- Summer ... so it is also the time for them to be ... is, ,When thunder roars, go indoors," Mary Ann Cooper, director ... Illinois at Chicago, said in a prepared statement. "Decisions about ...
... Emageon Inc.,(Nasdaq: EMAG ), a leader ... networks and imaging facilities,announced today that the Strategic ... Jefferies and Company as Lead Advisor and SunTrust,Robinson ... it evaluates all,strategic options available to the company., ...
... MANHATTAN BEACH, Calif., July 11 A,democratic process involving ... July 14 with hearings to determine the best way ... have the greatest strength,to win for their families and ... step in a thorough, open, and democratic,discussion to make ...
... $500 million in cuts, WASHINGTON, July 11 ... and pay more out of pocket,for health care, while ... legislation approved this week by the U.S. Congress., ... from the,Medicare Advantage program over a five-year period, including ...
... Texas, July 11 Abuelo,s restaurants today,released the ... been linked to consumption of certain raw jalapeno ... recommendation of the Centers for Disease Control (CDC),Abuelo,s ... our recipes and,plate presentations at this time. We ...
... In New York, the majority of Medicaid LTC Funds ... A new report by AARP,s,Public Policy Institute finds mixed ... long-term care (LTC) options under Medicaid.,According to the report, ... Medicaid LTC dollars for older people providing home and ...
Cached Medicine News:Health News:Summer Is Peak Time for Lightning Strikes 2Health News:Florida Seniors' Medicare Advantage Benefits at Risk 2Health News:New AARP Report Finds Mixed Results Among State Governments' Efforts to Balance Long Term Care Services Under Medicaid 2Health News:New AARP Report Finds Mixed Results Among State Governments' Efforts to Balance Long Term Care Services Under Medicaid 3
... Eppendorf Reference Series 2000 Pipette is a ... a compact and robust design, and superior ... used to operate the measuring stroke and ... Product features:Eppendorf "pipette/tip" system ensures utmost accuracy ...
... Finnpipette Focus from Thermo Labsystems ... ergonomics with uncompromising performance. ... offers a custom fit for ... shorter tip cones allow easier ...
... Focus from Thermo Labsystems was ... with uncompromising performance. The ... a custom fit for different ... tip cones allow easier and ...
... Finnpipette Focus from Thermo Labsystems ... ergonomics with uncompromising performance. ... offers a custom fit for ... shorter tip cones allow easier ...
Medicine Products: